Tectonic Therapeutic, Inc.
General ticker "TECX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $420.5M (TTM average)
Tectonic Therapeutic, Inc. follows the US Stock Market performance with the rate: 32.9%.
Estimated limits based on current volatility of 5.3%: low 33.67$, high 37.42$
Factors to consider:
- Total employees count: 60 (+17.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Need substantial additional funding, Commercialization failure, Intellectual property risks, Third-party risks
- Current price 54.5% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.84$, 22.79$]
- 2026-12-31 to 2027-12-31 estimated range: [5.69$, 15.60$]
Financial Metrics affecting the TECX estimates:
- Negative: with PPE of -5.0 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 96.28 > 64.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.04 > -0.60
- Negative: -0.75 < Inventory ratio change, % of 0
Short-term TECX quotes
Long-term TECX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $44.65MM | $58.02MM | $84.04MM |
| Operating Income | $-44.65MM | $-58.02MM | $-84.04MM |
| Non-Operating Income | $1.82MM | $0.03MM | $11.12MM |
| Interest Expense | $0.15MM | $0.11MM | $0.06MM |
| R&D Expense | $36.97MM | $41.36MM | $63.49MM |
| Income(Loss) | $-42.82MM | $-57.98MM | $-72.92MM |
| Taxes | $0.00MM | $0.00MM | $1.23MM |
| Net Income(Loss)* | $-42.82MM | $-57.98MM | $-74.15MM |
| Stockholders Equity | $94.74MM | $140.78MM | $251.33MM |
| Assets | $101.09MM | $152.91MM | $261.04MM |
| Operating Cash Flow | $-40.68MM | $-59.08MM | $-60.08MM |
| Capital expenditure | $0.28MM | $0.16MM | $0.21MM |
| Investing Cash Flow | $-0.28MM | $-0.16MM | $-0.14MM |
| Financing Cash Flow | $33.75MM | $171.71MM | $173.35MM |
| Earnings Per Share** | $-11.59 | $-3.93 | $-4.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.